TITLE: Implantation of Drug Eluting Stents during Percutaneous Coronary Interventions: Review of Revascularization Rates due to In-Stent Restenosis
|
|
- Stewart Patterson
- 5 years ago
- Views:
Transcription
1 TITLE: : Review of Revascularization Rates due to In-Stent Restenosis DATE: 15 September 2010 CONTEXT AND POLICY ISSUES: Coronary artery disease (CAD) is a leading cause of morbidity and mortality throughout the world. 1 The underlying cause of CAD is the deposition of atherosclerotic plaques in the coronary arteries, which leads to stenosis, reduced blood flow, and ischemia. 2 Revascularization procedures such as coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are used to correct the narrowing of the coronary blood vessels and restore blood flow to the ischemic areas. 2 During PCI, a catheter is threaded from an artery in the groin and advanced through the artery to the area of stenosis. Expandable bare metal stents (BMS) and drug eluting stents (DES) may then be placed to open the vessel or maintain vessel patency following PCI. PCI can also be performed without stenting, for example in areas where a stent cannot be placed. Drug eluting stents are metal stents that are covered with a polymer and an immunosuppressant or cytotoxic drug. 4 The drugs are incorporated to inhibit cell proliferation within the stent which may contribute to restenosis, a complication which was observed with BMS and prompted the development of DES. 4 There are a number of DES available in Canada that incorporate the drugs sirolimus (also referred to as rapamycin), paclitaxel, zotarolimus, and everolimus. 5 The risk of in-stent restenosis may be reduced with DES, but is not eliminated and when this complication occurs, revascularization procedures maybe required. 2 Revascularization may involve the target lesion (TLR), the target vessel (TVR), or total revascularization (TR). 2 An understanding of the frequency with which these complications occur could be helpful in budgeting and resource planning for facilities that perform PCI with DES implantation. This report will review the rates of revascularization specifically related to in-stent restenosis in patients undergoing PCI, for DES presently available in Canada. Disclaimer: The Health Technology Inquiry Service (HTIS) is an information service for those involved in planning and providing health care in Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material. It may be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners own terms and conditions.
2 RESEARCH QUESTION: What is the rate of revascularization due to in-stent restenosis in patients who received drug eluting stents during percutaneous coronary interventions? METHODS: A limited literature search was conducted on key health technology assessment resources, including PubMed, The Cochrane Library (Issue 8, 2010), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI (Health Devices Gold), EuroScan, international health technology agencies, and a focused Internet search. The search was limited to English language articles published between January 1, 2005, and August 19, Filters were applied to limit the retrieval to health technology assessments, systematic reviews, metaanalyses and randomized controlled trials. Outcomes of interest for this rapid review were rates of in-stent restenosis leading to TLR, instent restenosis leading to TVR, and in-stent restenosis leading to TR, including coronary arterial bypass graft (CABG). As such, studies were only included if they specified that a repeat revascularization procedure was performed due to restenosis or narrowing of the target lesion or stented segment, which generally included the stent and 5 mm distal and proximal to the stent. Studies that reported only TVR or TR as outcomes were excluded since the revascularization procedure could be unrelated to restenosis in the stent or stented segment. Studies that exclusively enrolled patients with diabetes were also excluded since this patient population is known to be at greater risk for restenosis and rates of revascularization may not be generalizable to the broader population. 6 As well, studies of DES that incorporated biolimus and abciximab were excluded as they are not available in Canada. Study quality of the included RCTs was assessed using the Jadad Scale. 7 In assessing study quality the Jadad Scale considers whether studies were randomized, the method by which the randomization sequence was generated, whether studies were blinded, the method of blinding and whether there was a description of withdrawals and dropouts. Scores on the Jadad Scale range from zero to five; studies with scores from zero to two are considered lower quality and studies with scores of three to five are considered higher quality. SUMMARY OF FINDINGS: Four relevant meta-analyses 8-11 and 18 additional RCTs were identified by the literature search. Three other relevant RCTs were identified but were included in one or more of the 0-2 meta-analyses so are not summarized individually in the present report. Systematic reviews and meta-analyses The four included meta-analyses 8-11 were pooled patient level analyses of various pivotal trials of one brand of paclitaxel eluting stent (PES) (TAXUS ). None of the meta-analyses were based upon systematic review of the literature; rather they selected specific double-blind RCTs of the TAXUS stent for inclusion. In all studies, the clinical efficacy of the TAXUS stent was compared to a BMS. Outcomes were assessed at different time intervals post-procedure, ranging from nine months to five years. Clinically driven TLR, or TLR not restricted to being 2
3 clinically driven were the outcomes of interest, as defined in Table 1. Three to four studies were included in each of the pooled analyses. The number of patients included in the pooled analyses who received the TAXUS stent ranged from to 1718, 11 and ranged from to for the BMS. Reported rates of any TLR at one year or less following stenting ranged from 2.9% to 12.2% for the TAXUS stents, compared to 15.% to 21.1% for BMS. The highest rates of TLR were observed during the first year of follow-up (2.9% to 12.2%). The rate of TLR 1 to 5 years following stenting with the TAXUS stent was 1.4% annualized 8 and was 1.6% annualized 9 2 to 5 years following the procedure. The rate for the BMS after 1 to 5 years was 1.7% annualized 8 and after 2 to 5 years was 2.0% annualized. 9 Two pooled analyses had conclusions specific to the rate of TLR. Based on one of the pooled analyses, it was concluded that the TAXUS stent reduced the risk of TLR in the first year, but not subsequent years. 9 The authors of the second pooled analysis concluded that the TAXUS stent reduced the risk of repeat revascularization, including TLR using CABG. 10 The four pooled analyses were limited by the inclusion of select studies of the TAXUS stent, rather than all available studies identified through systematic review. This could potentially bias the results and limit generalizability. Table 1: Pooled Patient Level Analyses of TAXUS PES* compared to BMS Authors, Year Population and Study Designs Intervention and Comparator Outcome Conclusion Uchida et al., stable ischemic syndromes and a single target lesion in a native coronary vessel. PES (n=605) BMS (n=292) Clinically driven TLR: Revascularization to treat instent restenosis or within 5 mm of the stent borders; >70% diameter stenosis by angiography or between 50% and 70% diameter stenosis with objective evidence of ischemia No conclusions specific to the TLR rates. Three RCTs (TAXUS IV, TAXUS V- DN, TAXUS ATLAS-WH) Leon et al., simple ( RCTs) or complex (1 RCT) lesions Four RCTs in total (TAXUS I, TAXUS II, TAXUS IV, PES (n=1400) BMS (n=197) TLR at less than 1 year: PES: 2.9% BMS: 15.% p-value not reported. Annualized TLR between 1 to 5 years: PES: 1.4% BMS: 1.7% p-value not reported. TLR: Revascularization to treat in-stent restenosis or within 5 mm of the stent borders. TLR at 1 year: PES: 7.5% BMS: 17.6% p< Annualized TLR between 2 to PES reduces the need for TLR in the first year following the procedure, but not the rate of late TLR.
4 Authors, Year Population and Study Designs and TAXUS V) Martin et al., stable ischemic syndromes and a single target lesion in a native coronary vessel. Three RCTs (TAXUS II, TAXUS IV, and TAXUS V) Intervention and Comparator PES (n=169) BMS (n=167) Outcome 5 years: PES: 1.6% BMS: 2.0% p=0.19 Clinically driven TLR (Total TLR): Revascularization (with PCI or CABG) to treat in-stent restenosis or within the 5 mm of the stent borders; >70% diameter stenosis with recurrent symptoms only or 50% diameter stenosis with objective evidence of ischemia. Total TLR at median followup of 9 months: PES: 12.2% BMS: 21.1% p<0.001 Conclusion The use of PES reduces the risk of repeat revascularization, including TLR using CABG. TLR-CABG: TLR as defined as above, but revascularization procedure performed with CABG, not PCI. TLR-CABG at median followup of 9 months: PES: 1.2% BMS:.0% p=0.002 Stone et al., stable ischemic syndromes and a single target lesion in a native coronary vessel. Four RCTs (TAXUS-II, PES (n=1718) BMS (n=1727) Cumulative TLR-CABG at 5 years: PES: 1.4% BMS: 4.1% p<0.001 Ischemia driven TLR: repeat revascularization (PCI or CABG) for ischemia with restenosis (diameter stenosis >50% within the stent or within 5mm of the stent borders) with ECG changes at rest or a positive functional study or a >70% diameter stenosis with recurrent symptoms only. No conclusions specific to TLR 4
5 Authors, Year Population and Study Designs TAXUS-IV, TAXUS-V, and TAXUS- VI) Intervention and Comparator Outcome TLR after median duration of follow-up of.2 years: PES: 7.9% BMS: 16.8% p< Conclusion *TAXUS is a brand of paclitaxel eluting stent; TLR: Target lesion revascularization; PES: paclitaxel eluting stent; BMS: bare metal stent; ECG: electrocardiogram; CABG: coronary artery bypass graft; PCI: percutaneous intervention; RCT: randomized controlled trial Randomized controlled trials Eighteen relevant RCTs were included, the characteristics of which are outlined in Table 2. The studies involved comparisons between 1) DES and BMS; 2) head-to-head comparisons between two different DES; or ) both head-to-head comparisons between two different DES and comparison to BMS. Fifteen of the 18 included studies were considered higher quality as assessed by the Jadad scale. Most studies were either open-label or single-blind RCTs, but two were double-blinded using DES and BMS that were indistinguishable from each other. 20,27 In the single-blind RCTs, the individual performing the procedure was not blinded, but patients and/or the individuals assessing outcomes were blinded to treatment allocation. Duration of follow-up ranged from six months to five years. Some studies focused on specific patient populations. For example, three studies included only patients with saphenous vein grafts; 17,24,25 one study included only patients with restenosis of previously implanted stents, 1 while three studies included only patients with ST-elevation myocardial infarction (MI). 18,21,22 Other studies were carried out in more general populations, for example patients with ischemia. 15,16,27 Specific inclusion and exclusion criteria for each study can be found in the appendix. Table 2: Characteristics of Included Randomized Studies Authors, Year Design Population Duration of Follow-up Intervention Comparator Quality Score Serruys et al., Multicenter, open-label, active control Mehilli et al., Twocentre, open-label, active control Rasmussen et al., Multicenter, singleblind, active chronic, stable CAD or ACS, including MI with or without STsegment elevation. restenosis of a SES who were undergoing revascularization procedures to correct chronic stable CAD or ACS 12 months ZES n= months SES n= months ZES n=1162 EES n=1126 PES n=225 SES n=
6 Authors, Year Design Population Duration of Follow-up Intervention Comparator Quality Score control Byrne et al., Twocentre, open-label, active control ischemia 2 year followup of Byrne et al, SES n=5 Dual-DES n= ZES n=9 Byrne et al., Twocentre, open-label, active control ischemia 12 months SES n=5 Dual-DES n= ZES n=9 Brilakis et al., Multicentre, single-blind Lee et al, Multicenter, open-label, active control Mehilli et al., Multicentre, singleblind, active control Silber et al., Multicenter, doubleblind Stone et al., Multicentre, Dirksen et al., symptomatic CAD undergoing PCI for unprotected left main CAD Patients requiring revascularization of a single, primary lesion in native coronary arteries STsegment elevation MI Patient with acute ST-elevation MI open label Twocentre, single-blind Patients requiring a SVG lesion stenting ST- Elevation MI 12 months PES n=9 12 months ZES n=108 2 years PES n=02 5 years SR PES n=11 MR PES n=15 1 year PES n= years PES n=10 BMS n=41 SES n=110 PES n=110 SES n=05 BMS n=270 BMS n= 749 BMS n=09 4 Wessely et al., Vermeersch et al., Single centre, blinding not reported Single centre, single-blind stable or unstable angina pectoris or a positive stress test one or more SVG 9 months PES n=45 year followup of Vermeersch et al., SES n=8 SES n=46 BMS n=7 6
7 Authors, Year Design Population Duration of Follow-up Intervention Comparator Quality Score Vermeersch et al., Suttorp et al., Single centre, single-blind Twocentre, single-blind one or more SVG total coronary occlusions. 6 months SES n=8 6 months SES n=100 BMS n=7 BMS n=100 Fajadet et al, and 2007 Multicenter, doubleblind Mehilli et al., Twocentre, active control evidence of ischemia Patients undergoing stenting in small coronary vessels 24 months ZES n=598 1 year SES n=180 BMS n=599 PES n=108 5 Windecker et al., Twocentre, singleblind, active control stable angina or ACS 9 months SES n=50 PES n=509 2 ACS: Acute coronary syndrome; CAD: Coronary artery disease; BMS: Bare Metal Stent; PES: paclitaxel eluting stent; DES: Drug eluting stent; Dual DES: sirolimus- and probucol-eluting stent; SES: sirolimus eluting stent; ZES: zotarolimus eluting stent; EES: everolimus eluting stent; MR PES: moderate-release polymer coated paclitaxel eluting stent; SR PES: slow-release polymer coated paclitaxel eluting stent; MI: myocardial infarction; SVG: saphenous vein graft Study outcomes are presented in Table along with the definitions used for the endpoint of TLR and the authors conclusion. There was variation in the rates of revascularization due to in-stent restenosis, with different included patient populations, definitions of TLR, timing of outcome assessment, and type of stent (DES or BMS). In most studies that compared DES to BMS, the rate of TLR was lower with DES than with BMS within the first 12 months of follow-up. In two studies with longer durations of follow-up, the differences in the rates of TLR between BMS and sirolimus eluting stents (SES) or paclitaxel eluting stents (PES) were not statistically significant. 22,24 One study that compared BMS to zotarolimus eluting stents (ZES) found a lower rate of TLR with ZES after 2 years. 27 After 12 months of follow-up, the rate of TLR with PES ranged from 4.5% 21 to 14.7% 28 and ranged from 4.5% to 10.% after five years. 20 After 12 months of follow-up the rate of TLR with SES ranged from 2.0% 14 to 16.6% 1 and was 10.7% after two years in one study. 19 After 12 months of follow-up the rate of TLR with ZES ranged from.9% 12 to 1.6% 16 and was 6.5% after two years. 27 The everolimus eluting stent (EES) was assessed in one of the included studies and it was found that after 12 months of follow-up the rate of TLR with EES was.4%. 12 7
8 Table : Outcomes and Conclusions of Included Randomized Controlled Trials Authors, Year Population Definition of Outcomes Results Conclusions Serruys et al., chronic, stable CAD or ACS, including MI with or without STsegment elevation. TLR at 12 months: ZES:.9% EES:.4% Difference: -0.6 (95% CI:-1.0 to 2.1); p=0.50 Mehilli et al., restenosis of a SES who were undergoing revascularization procedures to correct Rasmussen et al., chronic stable CAD or ACS Byrne et al., ischemia Clinically indicated TLR - diameter stenosis > 50% on angiography and one of the following (1) a positive history of recurrent angina pectoris, presumably related to the target vessel; (2) objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel; () abnormal results of any invasive functional diagnostic test; (4) a TLR with a diameter stenosis > 70% even in the absence of ischemic signs or symptoms. TLR: revascularization procedure involving the target lesion due to luminal re-narrowing in the presence of symptoms or objective signs of ischemia TLR: repeat revascularization caused by in-stent stenosis or within a 5 mm of the stent borders TLR: any revascularization procedure involving the target lesion due to luminal re-narrowing in the presence of symptoms or objective signs of ischemia TLR at 12 months: SES: 16.6% PES: 14.6% p= 0.52 TLR at 9 months: ZES: 4% SES: 1% p< HR: 4.25 (95% CI: 2.26 to 7.97) TLR at 12 months: ZES: 6% SES: 2% p< HR:.66 (95% CI: 2.2 to 6.01) Change in TLR between year 1 and year 2: Dual-DES: 0.9% SES.6% p=0.009 ZES was as safe and effective as the EES For the treatment of SES restenosis, SES and PES had comparable safety and efficacy. In routine clinical care, there were more major adverse cardiac events in 9 months and 18 months with ZES compared to SES. No evidence of different safety profiles for SES, Dual-DES, and ZES Byrne et al., ischemia TLR: any revascularization procedure involving the Dual-DES: 0.9% ZES:0.7% p=0.72 TLR at 12 months Dual-DES: 6.8% Dual-DES was superior to ZES 8
9 Authors, Year Population Definition of Outcomes Results Conclusions target lesion due to luminal re-narrowing in the presence of symptoms or objective signs of ischemia SES 7.2% p=0.8 Brilakis et al., Patients requiring SVG lesion stenting Lee et al, ST Elevation MI Mehilli et al., symptomatic CAD undergoing PCI for unprotected left main CAD Silber et al., Patients requiring revascularization of a single, primary lesion in native coronary arteries Ischemia driven TLR: repeat PCI or CABG due to restenosis of the target lesion in conjunction with angina or objective evidence of myocardial ischemia Ischemia driven TLR: Diameter stenosis 70% by quantitative coronary angiography or 50% to 70% diameter stenosis in the presence of ischemic symptoms or signs documented by functional stress testing. TLR: repeat PCI involving the left main area or CABG involving at least 1 of the main left coronary vessels due to luminal renarrowing in the presence of symptoms or objective signs of ischemia TLR: Revascularization to treat restenosis of the analysis segment (stent plus the 5-mm regions from the stent borders). Dual-DES: 6.8% ZES:1.6% p=0.001 TLR at 12 months: PES: 5% BMS: 28% p=0.00 Cumulative incidence of ischemia driven TLR at 12 months: No significant differences between groups (p=0.74); data not reported TLR at 1 year: PES: 6.5% SES: 7.8% p=0.49 TLR at 2 years: PES: 9.2% SES: 10.7% p=0.47 Overall TLR at Five Years: BMS: 18.4% SR PES: 10.%; p=0.0 vs BMS MR PES: 4.5%; p<0.001 vs BMS PCI TLR at Five Years: BMS: 16.5% SR PES: 7.9%; p=0.02 vs BMS MR PES:.7%; p<0.001 vs BMS CABG TLR at Five Years: BMS: 2.6% SR PES: 2.%; p=0.87 vs BMS and comparable to SES in terms of anti-restenotic performance PES use in SVG lesions had lower rates of target vessel failure. Larger studies are needed to confirm the benefit. DESs may be safe and effective in treating ST Elevation MI; no differences in major adverse cardiac events with the three included types of DESs PES and SES have similar outcomes in patients with unprotected left main CAD. Initial 6-month and 2-year reduction in TLR with TAXUS SR and MR stents compared to BMS was sustained through 5 years. 9
10 Authors, Year Population Definition of Outcomes Results Conclusions MR PES: 0.7%; p=0.22 vs BMS Stone et al., STsegment elevation MI Dirksen et al., Patient with acute ST-elevation MI Wessely et al., stable or unstable angina pectoris or a positive stress test Vermeersch et al., one or more SVG Ischemia driven TLR: Stenosis > 50% of the diameter of the target lesion, as documented by a positive functional study, ischemic changes on electrocardiogram, or symptoms referable to the target lesion; stenosis of >70% without symptoms of ischemia. TLR: ischemia-driven percutaneous revascularization of target lesion due to in-stent restenosis or restenosis within 5 mm distal or proximal to the stent TLR: revascularization of the target lesion due to restenosis in the presence of clinical ischaemic symptoms or a positive stress test TLR: Repeated revascularization procedure (PCI or CABG), as the result of restenosis in the stented segment. Overall TLR at 1 year: BMS: 7.5% PES: 4.5%; p=0.002 PCI TLR at 1 year: BMS: 6.6% PES: 4.0%; p=0.004 CABG TLR at 1 year: BMS: 1.0% PES: 0.5%; p=0.12 Cumulative incidence of TLR over 2 years: PES: 6.0% BMS:9.9% p=0.09 RR: 0.60 (95% CI: 0.4 to 1.09) TLR at 9 months: PES: 26.7% SES: 8.7% p=0.02 RR:.07 (95% CI: 1.07 to 8.80) TLR at years: SES: 19% BMS: 26% p=0.9 PES reduces restenosis and ischemia necessitating repeat revascularization procedure at one year compared to BMS. No significant benefit demonstrated by using PES compared to BMS. Results imply that SES is more efficient for the prevention of coronary restenosis than PES. Initial reduction in repeated revascularization procedures shown with the use of SES was lost at longerterm follow-up. Vermeersch et al., one or more SVG TLR: Repeated revascularization procedure (PCI or CABG), as the result of restenosis in the stented segment. TLR at 6 months: SES: 5.% BMS: 21.6% p=0.047 RR: 0.24 (95% CI: 0.05 to 1.0) More studies needed to make conclusions about the safety or harm of using SES for SVG lesions. In diseased SVGs, SES significantly reduced the binary restenosis rate and repeated TLR and TVR procedures. 10
11 Authors, Year Population Definition of Outcomes Results Conclusions Suttorp et al., total coronary occlusions. Fajadet et al, and 2007 evidence of ischemia Mehilli et al., Patients undergoing stenting in small coronary vessels Windecker et al., stable angina or ACS TLR: ischemia-driven percutaneous or surgical revascularization of target lesion due to in-stent restenosis or restenosis within 5 mm distal or proximal to the stent TLR: repeat revascularization to treat ischemia related to stenosis of 50% or more of the lumen diameter within the stent or within the 5 mm regions proximal and distal to the stent borders. TLR: revascularization procedure involving the target lesion due to luminal re-narrowing in the presence of symptoms or objective signs of ischemia TLR: revascularization for a stenosis within the stent or within the 5 mm borders adjacent to the stent. TLR at 6 months: SES: 4% BMS: 19% p<0.001 RR: 4.75 (95% CI: 1.68 to 1.47) TLR at 9 months: ZES: 4.6% BMS: 11.8% p< TLR at 12 months: ZES: 5.9% BMS: 1.1% (P<0.0001). TLR at 24 months: ZES: 6.5% BMS: 14.7% (P<0.0001). TLR at 12 months: SES: 6.6% PES: 14.7% p= RR: 2.24 (95% CI: 1.20 to 4.17) Total TLR at 9 months: SES: 4.8% PES: 8.% HR: 0.56 (95% CI: 0.4 to 0.9); p=0.0 Percutaneous TLR at 9 months: SES: 4.4% PES:7.1% HR: 0.61 (95% CI: 0.6 to 1.0); p=0.06 SES superior to BMS in patients with total coronary occlusions with significant reduction in restenosis, resulting in decreased need for target lesion and target vessel revascularization. ZES stent can be recommended for PCI to treat coronary artery stenosis as it is highly deliverable, with anti-restenosis properties and is safe to use in the population included in the study. SES has a lower incidence of angiographic restenosis and a reduced need for target lesion revascularization in patients with lesions in small coronary vessels. SES use was associated with fewer major adverse cardiac events by decreasing the rate of restenosis 11
12 Authors, Year Population Definition of Outcomes Results Conclusions Surgical TLR at 9 months: SES: 0.6% PES: 1.8% HR: 0. (95% CI: 0.10 to 1.22); p=0.10 ACS: Acute coronary syndrome; CAD: Coronary artery disease; BMS: Bare Metal Stent; PES: paclitaxel eluting stent; DES: Drug eluting stent; Dual DES: sirolimus- and probucol-eluting stent; SES: sirolimus eluting stent; ZES: zotarolimus eluting stent; EES: everolimus eluting stent; MR PES: moderate-release polymer coated paclitaxel eluting stent; SR PES: slow-release polymer coated paclitaxel eluting stent; MI: myocardial infarction; SVG: saphenous vein graft Limitations Four pooled analyses and 18 RCTs that assessed rates of TLR related to in-stent restenosis were included in this rapid review. While the majority of the included RCTs (15) would be considered higher quality according to the items assessed on the Jadad Scale, a number of limitations remain. First, rates of TLR due to in-stent restenosis differed depending on the timing of the outcome assessment. It remains unclear as to what the optimal time point would be to assess TLR related to in-stent restenosis. Further, just six of the 18 included studies followed patients past 12 months. Moreover, interpreting the rates of TLR related to in-stent restenosis is complicated by the fact that often the restenosis was detected only through angiography, not due to symptoms. Therefore, it is unclear if all cases where TLR was performed would be detected in a clinical setting in the absence of symptoms of ischemia. This would lead to higher rates of revascularization than what would be found in real-world settings. 4 Further, cointervention with anti-platelet regimens could potentially impact the observed rates of TLR related in-stent restenosis. Other factors that limit the ability to compare rates across studies include differences in timing of outcome assessment, patient populations, inclusion and exclusion criteria, and definitions of TLR. While four pooled analyses were identified and included, these analyses were not comprehensive systematic reviews and included only selected studies of one particular brand of PES which could potentially bias the study results and limit the generalizability to other DES. CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING: Based on the identified literature, rates of TLR for in-stent restenosis vary with the duration of time following the procedure, with the specific patient population, and with the type of DES that was used which complicates the ability to compare rates of TLR for in-stent restenosis between different DES. In general, however, the rate of revascularization due to in-stent restenosis with DES was lower than BMS, but it was unclear as to which of the DES had the lowest rate of revascularization in head to head comparisons. Resource planning with respect to the expected frequency with which TLR due to in-stent restenosis would be required should consider the time horizon, patient mix, and type of DES in use at the facility since rates of TLR for in-stent restenosis could potentially be influenced by such factors. 12
13 PREPARED BY: Health Technology Inquiry Service Tel:
14 REFERENCES: 1. Ko DT, Newman AM, Alter DA, Austin PC, Chiu M, Cox JL, et al. Secular trends in acute coronary syndrome hospitalization from 1994 to Can J Cardiol [Internet] Mar [cited 2010 Aug 19];26(): Available from: 2. Drug-eluting stents for the treatment of coronary artery disease [Internet]. London: National Institute for Health and Clinical Evidence; 2007 Jul. 48 p. (NICE technology appraisal guidance 152). [cited 2010 Aug 19]. Available from: Percutaneous coronary intervention (PCI or angioplasty with stent) [Internet]. In: Surgeries and other procedures. Ottawa: Heart and Stroke Foundation; 2007 Mar [cited 2010 Aug 19]. Available from: P ercutaneous_coronary_intervention_pci_or_angioplasty_with_stent.htm. 4. Rossini R, Musumeci G, Aprile A, Valsecchi O. Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. Expert Rev Pharmacoecon Outcomes Res Feb;10(1): Health Canada. Medical Devices Active Licence Listing [database on the internet]. Ottawa: Health Canada; c2007 -; 2010 [cited 2010 Aug 19]. Available from: 6. Mahmud E, Bromberg-Marin G, Palakodeti V, Ang L, Creanga D, Demaria AN. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol [Internet] Jun 24 [cited 2010 Aug 25];51(25): Available from: 7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials [Internet] [cited 2010 Aug 19];17(1):1-12. Available from: 8. Uchida T, Popma J, Stone GW, Ellis SG, Turco MA, Ormiston JA, et al. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions. JACC Cardiovasc Interv Apr;(4): Leon MB, Allocco DJ, Dawkins KD, Baim DS. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. JACC Cardiovasc Interv Jun;2(6):
15 10. Martin JL, Ellis SG, Colombo A, Grube E, Maloney T, Friedman MI, et al. Frequency of coronary artery bypass grafting following implantation of a paclitaxel-eluting or a baremetal stent into a single coronary artery. Am J Cardiol Jan 1;10(1): Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation [Internet] Jun 5 [cited 2010 Aug 26];115(22): Available from: Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med Jul 8;6(2): Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimuseluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol Jun 15;55(24): Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet Mar 27;75(9720): Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol Jun 8;55(2): Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymerbased drug-eluting stents. Eur Heart J [Internet] Apr [cited 2010 Aug 25];0(8):92-1. Available from: Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol Mar 17;5(11): Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with STelevation myocardial infarction. Am J Cardiol Nov 15;104(10): Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol [Internet] May 12 [cited 2010 Aug 25];5(19): Available from: 15
16 20. Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, et al. Final 5- year results of the TAXUS II trial: a randomized study to assess the effectiveness of slowand moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation [Internet] Oct 1 [cited 2010 Aug 26];120(15): Available from: Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxeleluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med [Internet] May 7 [cited 2010 Aug 26];60(19): Available from: Dirksen MT, Vink MA, Suttorp MJ, Tijssen JG, Patterson MS, Slagboom T, et al. Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. EuroIntervention May;4(1): Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schömig A. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J [Internet] Nov [cited 2010 Aug 25];28(22): Available from: Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol [Internet] Jul 17 [cited 2010 Aug 25];50(): Available from: Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol [Internet] Dec 19 [cited 2010 Aug 25];48(12): Available from: Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation [Internet] Aug 29 [cited 2010 Aug 25];114(9): Available from: Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholineencapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation [Internet] Aug 22 [cited 2010 Aug 26];114(8): Available from: 16
17 28. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J [Internet] Feb [cited 2010 Aug 25];27(): Available from: Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, et al. Sirolimuseluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med [Internet] Aug 18 [cited 2010 Aug 26];5(7): Available from: 0. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drugeluting stents in contemporary clinical practice. Circulation [Internet] Nov 22 [cited 2010 Aug 25];112(21):06-1. Available from: 1. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA Sep 14;294(10): Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J [Internet] Nov [cited 2010 Aug 25];28(21): Available from: Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholineencapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol Feb;55(1): Drug-eluting coronary stents: many meta-analyses, little benefit. Prescrire Int Apr;18(100):
18 APPENDIX: INCLUSION AND EXCLUSION CRITERIA FOR THE INCLUDED RANDOMIZED CONTROLLED TRIALS Authors, Year Inclusion Criteria Exclusion Criteria Serruys et al., At least one coronary lesion with stenosis of >50% in a vessel with a reference diameter of 2.25 to 4.0 mm. Mehilli et al., >18 years of age with ischemic symptoms or evidence of myocardial ischemia with 50% restenosis located in a vessel segment treated with SES Rasmussen et al., > 18 years or older, chronic stable CAD or ACS, at least one target lesion Byrne et al., > 18 years with ischemic symptoms or evidence of myocardial ischemia in with 50% de novo stenosis located in native coronary vessels. Byrne et al., > 18 years with ischemic symptoms or evidence of myocardial ischemia in with 50% de novo stenosis located in native coronary vessels. Brilakis et al., > 18 years with one or more de novo or restenotic (50 to 99%) lesions in the SVG, need for PCI and willingness to participate in follow-up Lee et al, Chest pain > 0 minute duration, 12 hours or less following onset of symptoms, and ST-segment elevation (>1 mm in 2 standard leads or > 2 mm in 2 contiguous precordial leads). Mehilli et al., > 18 years with ischemic symptoms or evidence of myocardial ischemia with > 50% de novo stenosis in the left main stem Known intolerance to a study drug, metal alloys, or contrast media; planned surgery within 6 months after the index procedure; childbearing potential; and participation in another trial before reaching the primary end point. Target lesion in left main stem, acute MI within the preceding 48 hours, cardiogenic shock, malignancies, comorbid conditions with life expectancy <12 months, allergy to sirolimus or paclitaxel, or pregnancy Could not provide informed consent, life expectancy < 1 year; allergy to study drug, or participating in another RCT. Target lesion in left main stem, in-stent restenosis, cardiogenic shock, malignancies or other comorbid conditions with life expectancy < 12 months, allergy to aspirin, clopidogrel, sirolimus, stainless steel, or pregnancy Target lesion in left main stem, in-stent restenosis, cardiogenic shock, malignancies or other comorbid conditions with life expectancy < 12 months, allergy to aspirin, clopidogrel, sirolimus, stainless steel, or pregnancy Prior brachytherapy of the target vessel, LVEF < 25%, contraindication to study medication, use of colchicine, prior use of paclitaxel, elevated serum creatinine, leukocytes, pregnancy or breast feeding, life expectancy < 24 months. Administration of fibrinolytic agents, documented left ventricular ejection fraction <0%, cleft main coronary artery disease, history of MI, cardiogenic shock, and life expectancy <12 months. ST-segment elevation MI within 48 h of symptom onset; prior bypass graft surgery; in-stent restenosis; cardiogenic shock; comorbid conditions with life expectancy <1 year; left main size > 4.5 mm; planned PCI procedure within 0 days; planned elective surgery that would require stopping clopidogrel within six months, allergy to study medications; pregnancy. Silber et al., > 18 years old, stable or unstable Recent coronary intervention in past 0 18
19 Authors, Year Inclusion Criteria Exclusion Criteria angina or silent ischemia, days, left ventricular ejection fraction <0%, candidates for PCI or CABG. evolving MI, left main coronary disease, or prespecified need to implant more than one 15 mm stent. Single target lesion with estimated stenosis 50% and 99%, estimated length 12 mm, and location in a native coronary vessel.0 mm and.5 mm in diameter. Stone et al., > 18 years, presented within hours after the onset of symptoms, ST-segment elevation of 1 mm or more in two or more contiguous leads, new left BBB, or true posterior MI Dirksen et al., Acute MI with ST-Elevation, reperfusion expected to be achieved within six hours of symptom onset Wessely et al., > 18 years old, admitted with stable or unstable angina pectoris or a positive stress test with de novo lesions in a native coronary vessel and who were undergoing stenting. Vermeersch et al., 18 to 85 years old, history of previous CABG, stable or unstable angina, and with de novo target lesions (>50% stenosis) localized diseased SVG with a reference vessel diameter >2.5 and <4.0 mm. Vermeersch et al., 18 to 85 years old, history of previous CABG, stable or unstable angina, and with de novo target lesions (>50% stenosis) localized diseased SVG with a reference vessel diameter >2.5 and <4.0 mm Suttorp et al., Duration of the total coronary occlusion of 2 weeks with ischemia related to the target vessel Fajadet et al, Ischemia or positive function study and 2007 requiring stenting of a single native coronary vessel that had not been previously treated Mehilli et al., Angina pectoris and/or a positive stress test in the presence of Contraindications to study medications, conditions that increase the risk of hemorrhage, and unable to take clopidogrel for six months. Cardiogenic shock prior to randomization, uncertain neurological outcome after resuscitation, mechanical ventilation, life expectancy less than 12 months. ST-elevation MI within 48 h before admission, lesions involving the left main coronary artery, and patients with contraindications to the study medications. Myocardial infarction within the previous 7 days, LVEF left ventricular ejection fraction <25%, impaired renal function, distal graft anastomotic stenosis, totally occluded SVGs, previous brachytherapy treatment in the index vessel, or and allergy to study medications. Myocardial infarction within the previous 7 days, LVEF left ventricular ejection fraction <25%, impaired renal function, distal graft anastomotic stenosis, totally occluded SVGs, previous brachytherapy treatment in the index vessel, or and allergy to study medications. Lesion could not be crossed, use of heparin, aspirin, and clopidogrel prohibited, severe renal failure or patients were unwilling or unable to complete follow-up. LVEF <0%, >50% stenosis near the target lesion, MI within the past 72 hours, hypersensitivity to the study medications or contrast media, participation in another trial, coronary interventional procedure in the previous 0 days or planned after implantation of the stent. Acute MI within 48 hours, target lesion located in left main trunk, in-stent 19
20 Authors, Year Inclusion Criteria Exclusion Criteria angiographically significant stenosis in native coronary vessels with a diameter of < 2.8 mm. Windecker et al., 1 lesion with stenosis of 50% in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation. restenosis, pregnancy, contraindications to study medications, lack of consent to participate in the study, diabetes mellitus Allergy to study drugs, participation in another coronary-device study; and terminal illness. 20
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationDATE: 04 April 2012 CONTEXT AND POLICY ISSUES
TITLE: Procedure Site Bleeding Complications Following Percutaneous Coronary Interventions or Angioplasty: A Review of Clinical Evidence and Guidelines DATE: 04 April 2012 CONTEXT AND POLICY ISSUES Percutaneous
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationA Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents
ISPUB.COM The Internet Journal of Cardiology Volume 3 Number 2 A Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents M Sondhi, A Jagannath, J
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationPaclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationLong-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023
More informationZotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 7, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.03.001
More informationClinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents
ORIGINAL ARTICLE Korean J Intern Med 2013;28:72-80 Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents Jang-Won
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationAngiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions
244 U. Gerk, B. Leithäuser, U. Schäfer, F. Jung, J.-W. Park Applied Cardiopulmonary Pathophysiology 14: 244-249, 2010 Angiographic long-term results after implantation of the paclitaxel-eluting coronary
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationOne-year Outcome of Stenting for Long Coronary Lesions, a Prospective Clinical Trial
Tabriz University of Medical Sciences Original Article One-year Outcome of Stenting for Long Coronary Lesions, a Prospective Clinical Trial Samad Ghaffari MD, Mohammad Reza Hasanian MD, Leili Pourafkari
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationEvaluation of a novel stent technology: the Genous EPC capturing stent Klomp, M.
UvA-DARE (Digital Academic Repository) Evaluation of a novel stent technology: the Genous EPC capturing stent Klomp, M. Link to publication Citation for published version (APA): Klomp, M. (2012). Evaluation
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationTCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
More informationTITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationMID-TERM CLINICAL OUTCOMES OF ZOTAROLIMUS-ELUTING STENT IN PATIENTS WITH STABLE ANGINA PECTORIS
Pak Heart J ORIGINAL ARTICLE MID-TERM CLINICAL OUTCOMES OF ZOTAROLIMUS-ELUTING STENT IN PATIENTS WITH STABLE ANGINA PECTORIS 1 2 3 4 5 Yasir Adnan, Shahab Ud Din, Lubna Noor, Farooq Ahmad, Syed Tahir Shah,
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationComparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics
Original Article Comparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics Mynuddin Ahmed Nawaz 1, Ia Avaliani 1, Irakli Davitashvili 1, Georgi Getmansky 1 Khatuna Jalabadze
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationSirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
More information2-Year Patient-Related Versus Stent-Related Outcomes
Journal of the American College of Cardiology Vol. 60, No. 13, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.004
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Byrne RA, Stone GW, Ormiston J, Kastrati A.
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationClinical Study Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
Thrombosis Volume 2012, Article ID 126369, 8 pages doi:10.1155/2012/126369 Clinical Study Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More information3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 8, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.04.008
More informationIntroduction. Keywords vein grafts. Percutaneous coronary intervention Drug-eluting stent Bare metal stent Self-apposing stent Saphenous
Neth Heart J (2018) 26:94 101 https://doi.org/10.1007/s12471-017-1066-0 ORIGINAL ARTICLE Comparison between the STENTYS self-apposing bare metal and paclitaxel-eluting coronary stents for the treatment
More informationReview Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis
International Scholarly Research Network ISRN Cardiology Volume 2011, Article ID 675638, 6 pages doi:10.5402/2011/675638 Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationCount Down to COMBAT
Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of
More informationEffectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis
Journal of the American College of Cardiology Vol. 49, No. 5, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.049
More informationTITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety
TITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety DATE: 1 April 2010 CONTEXT AND POLICY ISSUES: The prevalence of epilepsy ranges from 0.5% to 1%, 1,2 and
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationLong-term Outcomes of Paclitaxel-Eluting Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention: A Meta-Analysis
META ANALYSIS Long-term Outcomes of Paclitaxel-Eluting Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention: A Meta-Analysis Jie Kong, Peng Liu, Xueqiang Fan, Jianyan Wen, Jianbin Zhang,
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationLong-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
www.nature.com/scientificreports Received: 11 October 2016 Accepted: 16 June 2017 Published online: 25 July 2017 OPEN Long-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES
More informationjournal of medicine The new england Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization abstract
The new england journal of medicine established in 1812 august 18, 2005 vol. 353 no. 7 Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization Stephan Windecker, M.D., Andrea Remondino,
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationConflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationLeft Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationImpact of Sex on Clinical and Angiographic Outcomes Among Patients Undergoing Revascularization With Drug-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 3, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.11.011 CLINICAL RESEARCH
More informationThe SORT OUT VI Trial
A Prospective, Randomized, "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Stents The SORT OUT VI Trial Bent Raungaard, Lisette
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationDual-therapy stent technology for patients with coronary artery disease Kalkman, D.N.
UvA-DARE (Digital Academic Repository) Dual-therapy stent technology for patients with coronary artery disease Kalkman, D.N. Link to publication Citation for published version (APA): Kalkman, D. N. (2018).
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationKang Gao, Yiguang Sun * , Ming Yang, Ling Han, Liwei Chen, Wenze Hu, Ping Chen and Xiaohong Li
Gao et al. BMC Cardiovascular Disorders (2017) 17:194 DOI 10.1186/s12872-017-0603-5 RESEARCH ARTICLE Open Access Efficacy and safety of polymer-free stent versus polymer-permanent drug-eluting stent in
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationSummary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A
Summary HTA HTA-Report Summary Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Scientific background The coronary heart
More informationRun-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators
I-LOVE-IT A Prospective, Multicenter Clinical Trial of TIVOLI Bioabsorbable Polymer Based Sirolimus-Eluting vs. ENDEAVOR Zotarolimus- Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationLamin King, 1 * MB MS, Robert A. Byrne, 1 MB BCh, PhD, Julinda Mehilli, 1 MD, Albert Schömig, 1,2 MD, Adnan Kastrati, 1 MD, and Jurgen Pache, 1 MD
Catheterization and Cardiovascular Interventions 81:E23 E28 (2013) Five-Year Clinical Outcomes of a Polymer-Free Sirolimus-Eluting Stent Versus a Permanent Polymer Paclitaxel-Eluting Stent: Final Results
More informationLate-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 5, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.12.014 Late-Term Clinical
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationTITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines
TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines DATE: 5 May 2009 RESEARCH QUESTION: What recommendations exist for
More information